组蛋白去乙酰化酶抑制剂治疗多发性骨髓瘤的研究现状  

Current research status of histone deacetylase inhibitors in treatment of multiple myeloma

作　　者：黄玉蓉 赵小英[1] 袁相贵[1] Huang Yurong;Zhao Xiaoying;Yuan Xianggui(Department of Hematology,Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,Zhejiang Province,China)

机构地区：[1]浙江大学医学院附属第二医院血液科,杭州310009

出　　处：《国际输血及血液学杂志》2020年第2期114-121,共8页International Journal of Blood Transfusion and Hematology

基　　金：浙江省科技厅重点科技创新团队项目(2011R50015)。

摘　　要：组蛋白乙酰化修饰为表观遗传学转录调控的重要环节,目前已成为肿瘤治疗研究领域的新热点。组蛋白乙酰化水平由组蛋白乙酰化酶(HAT)与组蛋白去乙酰化酶(HDAC)共同调控。多发性骨髓瘤(MM)为一种恶性浆细胞肿瘤。近年,研究发现HDAC在MM中过表达,并且伴HDAC过表达的MM患者预后较差。HDAC抑制剂(HDACi)治疗MM的疗效已在多个临床试验中得到证实,为颇具潜力的MM治疗药物。笔者拟就HDACi在治疗MM中的研究现状进行介绍。Histone acetylation is an important part of epigenetic regulation and has become a new hotspot in the field of tumor therapy currently.Histone acetylation levels are regulated by histone acetylase(HAT)and histone deacetylase(HDAC).Multiple myeloma(MM)is a kind of plasma cell malignancy.In recent years,HDAC has been found to be overexpressed in MM,and MM patients with HDAC overexpression have poor prognosis.Efficacy of HDAC inhibitor(HDACi)in the treatment of MM has been proved in many clinical trials.HDACi may be a promising drug against MM.This paper reviews the research status of HDACi in the treatment of MM.

关 键 词：多发性骨髓瘤 组蛋白去乙酰化酶 组蛋白去乙酰化酶抑制剂 表观基因组 药物疗法 

分 类 号：R733[医药卫生—肿瘤]